Paul Hartmann AG manufactures and sells medical and hygiene products for wound care, incontinence, disinfection, and surgical efficiency in Europe, North and South America, Africa, Asia, and Oceania.
The last earnings update was 67 days ago.
Discounted Cash Flow Calculation for OTCPK:PLHN.F using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
OTCPK:PLHN.F DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
Paul Hartmann's share price is below the future cash flow value, but not at a moderate discount (< 20%).
Paul Hartmann's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Paul Hartmann's earnings available for a low price, and how does
this compare to other companies in the same industry?
Paul Hartmann's earnings are expected to grow by 6.2% yearly, however this is not considered high growth (20% yearly).
Unable to determine if Paul Hartmann is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Paul Hartmann's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
1/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Britta Fuenfstueck has been Chief Executive Officer at Paul Hartmann AG since January 1, 2019 and its Management Board since January 1, 2019. Ms. Fuenfstueck served as Chairman of the Management Board at Paul Hartmann AG since January 1, 2019 until March 2019. Ms. Fuenfstueck has been a Member of Management Board at Paul Hartmann AG since November 1, 2018. She served as member of the Executive Committee at Clariant AG from 01 April 2016 till 2018. She served as the Chief Executive Officer of the Clinical Products Division at Siemens Healthcare since 2013. From 2000 to 2009, she held various marketing and sales positions, including, Vice President as well as director roles in strategy, planning and mergers & acquisitions in the healthcare division of Siemens AG in both Germany and the United States. as well as Director, Product Portfolio and Planning, Marketing and Sales, for Siemens' Magnetic Resonance Business Unit. In 2009, she became Chief Executive Officer of the Molecular Imaging Business Unit at Siemens in Chicago, USA. In 2013 she was appointed Chief Executive Officer of the Clinical Products division at Siemens in Erlangen (Germany). She began her career in 1998 as a consultant at Boston Consulting Group. Ms. Fuenfstueck, following an education in economics, studied engineering physics at the Johannes-Kepler-University of Linz (Austria), There she completed her MSc studies in 1998.
Insufficient data for Britta to compare compensation growth.
Insufficient data for Britta to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Paul Hartmann management team is over 5 years, this suggests they are a seasoned and experienced team.
CEO & Member of Management Board
CFO, Labor Director & Member of the Management Board
Chief Commercial Officer of Hygiene & Member of Management Board
Chief Process Officer & Member of the Management Board
Vice President of Corporate Legal
Vice President of Human Resources Management
Senior Vice President of Corporate Accounting
Head of Group Purchasing Management
Executive Managing Director of SANIMED Group Germany
Senior Vice President Business Unit Risk Prevention
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Paul Hartmann board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Chairman of Supervisory Board
Deputy Chairman of the Supervisory Board
Vice President Operations Management Medical Production & Member of Supervisory Board
Paul Hartmann AG manufactures and sells medical and hygiene products for wound care, incontinence, disinfection, and surgical efficiency in Europe, North and South America, Africa, Asia, and Oceania. The company offers disinfectant products for hands, surface, and instruments; cleaning, skin care, and skin antisepsis products, as well as Sterillium, a hand disinfectant; incontinence management products; and personal healthcare products, such as diagnostic devices and first aid products. It also provides single-use and pre-surgical products, disposable surgical gloves, clothing and gowns, and disposable drapes for use in operating theatres, treatment rooms, and wards; and wound management solutions, including traditional compresses, bandages, hydro therapy products. The company offers its products and services to nursing and healthcare professionals, home residents, and patients. Paul Hartmann AG was founded in 1818 and is based in Heidenheim, Germany.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.